NASDAQ:ALEC

Alector (ALEC) Stock Forecast, Price & News

$6.88

+0.85 (+14.10%)

(As of 09/22/2023 ET)

Compare

Today's Range: $6.28
▼
$6.93
50-Day Range: $5.20
▼
$8.77
52-Week Range: $4.98
▼
$10.07

Volume: 1.11 million shs
Average Volume: 580,559 shs
Market Capitalization: $576.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.89

Alector MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 116.4% Upside
$14.89 Price Target
Short Interest: Bearish
9.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 0.42
Based on 3 Articles This Week
Insider Trading: Selling Shares
$3.07 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.85) to ($2.36) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

506th out of 968 stocks

Biological Products, Except Diagnostic Industry

74th out of 160 stocks

4.3

Analyst's Opinion

Consensus Rating
Alector has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.89, Alector has a forecasted upside of 116.4% from its current price of $6.88.
Amount of Analyst Coverage
Alector has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.85% of the float of Alector has been sold short.
Short Interest Ratio / Days to Cover
Alector has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Alector has recently decreased by 3.31%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Alector does not currently pay a dividend.
Dividend Growth
Alector does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Alector is -0.92.

3.0

News and Social Media Coverage

News Sentiment
Alector has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Alector this week, compared to 1 article on an average week.
Search Interest
10 people have searched for ALEC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
2 people have added Alector to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,067,340.00 in company stock.
Percentage Held by Insiders
14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.71% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Alector are expected to decrease in the coming year, from ($1.85) to ($2.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alector is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alector is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Alector has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Alector (NASDAQ:ALEC) Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Price History

30 days | 90 days | 365 days | Advanced Chart

ALEC Stock News Headlines

September 22, 2023 | benzinga.com

Analyst Expectations for Alector's Future

September 15, 2023 | americanbankingnews.com

Alector, Inc. (NASDAQ:ALEC) Major Shareholder Sells $3,000,000.00 in Stock

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 9, 2023 | seekingalpha.com

Alector completes enrollments in mid-stage Alzheimer’s trial

September 8, 2023 | msn.com

Alector completes enrolment in AL002 trial to treat early Alzheimer’s

August 31, 2023 | msn.com

Alector (ALEC) Price Target Increased by 30.49% to 15.59

August 12, 2023 | msn.com

Mizuho Maintains Alector (ALEC) Buy Recommendation

August 10, 2023 | markets.businessinsider.com

Alector (ALEC) Receives a Buy from Mizuho Securities

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 9, 2023 | msn.com

Stifel Maintains Alector (ALEC) Hold Recommendation

August 8, 2023 | msn.com

Morgan Stanley Reiterates Alector (ALEC) Equal-Weight Recommendation

August 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Alector (ALEC) Buy Recommendation

August 4, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)

August 4, 2023 | marketwatch.com

Alector Up 31% After 2Q Results, Drug Program Update

July 27, 2023 | finance.yahoo.com

Alector to Host Mid-Year Earnings Conference Call

July 17, 2023 | msn.com

Alector: Immuno-Neurology Innovator But Wait For The Pipeline Success

July 7, 2023 | fool.com

Alector (NASDAQ: ALEC)

July 6, 2023 | msn.com

Alector (ALEC) Price Target Increased by 6.49% to 11.95

June 6, 2023 | finance.yahoo.com

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

May 18, 2023 | seekingalpha.com

Alector (ALEC) Investor Presentation - Slideshow

May 5, 2023 | finance.yahoo.com

Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price

May 2, 2023 | finance.yahoo.com

Alector to Participate in the BofA Securities 2023 Healthcare Conference

April 13, 2023 | finance.yahoo.com

Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years ago

February 28, 2023 | finance.yahoo.com

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 17, 2023 | finance.yahoo.com

Alector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64%

February 16, 2023 | finance.yahoo.com

Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?

January 28, 2023 | finance.yahoo.com

Alector, Inc. (ALEC) Stock Historical Prices & Data - Yahoo Finance

See More Headlines

Receive ALEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter.

ALEC Company Calendar

Last Earnings: 8/03/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALEC
CUSIP: N/A
CIK: 1653087
Web: www.alector.com
Phone: (415) 231-5660
Fax: N/A
Employees: 239
Year Founded: 2013

Price Target and Rating

Average Stock Price Forecast: $14.89
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +122.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-133,310,000.00
Net Margins: -140.18%
Pretax Margin: -136.51%
Return on Equity: -67.57%
Return on Assets: -18.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.90
Quick Ratio: 4.90

Sales & Book Value

Annual Sales: $133.62 million
Price / Sales: 4.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.59 per share
Price / Book: 2.58

Miscellaneous

Outstanding Shares: 83,830,000
Free Float: 72,094,000
Market Cap: $559.98 million
Optionable: Not Optionable
Beta: 0.75

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Arnon Rosenthal Ph.D. (Age 67)
Co-Founder, CEO & Director
Comp: $1.02M

Dr. Sara Kenkare-Mitra Ph.D. (Age 55)
Pres and Head of R&D
Comp: $1.19M

Dr. Marc Grasso M.D. (Age 50)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $738.05k

Dr. Gary Romano M.D. (Age 61)
Ph.D., Chief Medical Officer
Comp: $602.98k

Mr. Peter Heutink Ph.D.
Chief Scientific Officer

Ms. Danielle Pasqualone J.D.
Ph.D., Gen. Counsel

Erica Jefferson
VP of Communications & Public Affairs

Michelle Corral
VP of Communications & Investor Relations

Ms. Clare Hunt M.B.A.
Chief People Officer

Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALEC Stock - Frequently Asked Questions

Should I buy or sell Alector stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALEC shares.
View ALEC analyst ratings or view top-rated stocks.
What is Alector's stock price forecast for 2023?: 8 Wall Street research analysts have issued 12-month target prices for Alector's stock. Their ALEC share price forecasts range from $8.00 to $41.00. On average, they expect the company's share price to reach $14.89 in the next year. This suggests a possible upside of 122.9% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.
How have ALEC shares performed in 2023?: Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 27.6% and is now trading at $6.68.
View the best growth stocks for 2023 here.
When is Alector's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ALEC earnings forecast.
How were Alector's earnings last quarter?: Alector, Inc. (NASDAQ:ALEC) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.81) by $0.83. The business earned $56.21 million during the quarter, compared to the consensus estimate of $3.63 million. Alector had a negative net margin of 140.18% and a negative trailing twelve-month return on equity of 67.57%.
What ETF holds Alector's stock ?: iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.
What guidance has Alector issued on next quarter's earnings?: Alector issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90.00 million-$100.00 million, compared to the consensus revenue estimate of $29.07 million.
What is Arnon Rosenthal's approval rating as Alector's CEO?: 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alector own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).
When did Alector IPO?: (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.
What is Alector's stock symbol?: Alector trades on the NASDAQ under the ticker symbol "ALEC."
Who are Alector's major shareholders?: Alector's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.34%), Braidwell LP (4.93%), State Street Corp (3.24%), JPMorgan Chase & Co. (2.86%), Point72 Asset Management L.P. (2.07%) and Franklin Resources Inc. (1.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends.
How do I buy shares of Alector?: Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Alector's stock price today?: One share of ALEC stock can currently be purchased for approximately $6.68.
How much money does Alector make?: Alector (NASDAQ:ALEC) has a market capitalization of $559.98 million and generates $133.62 million in revenue each year. The company earns $-133,310,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.
How many employees does Alector have?: The company employs 239 workers across the globe.
Does Alector have any subsidiaries?: The following companies are subsidiares of Alector: Alector LLC.
Read More
How can I contact Alector?: Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.alector.com. The company can be reached via phone at (415) 231-5660 or via email at ir@alector.com.

This page (NASDAQ:ALEC) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial